Novartis
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Novartis sits in the top decile of US sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count).
Novartis: 265 sponsored US clinical trials, none currently recruiting.
Novartis sponsors 265 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 248 completed. 176 of these trials are in Phase 3-4 (later-stage) and 69 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 11 trials.
Top-decile sponsor footprint
Novartis ranks in the top decile of sponsors by registered trial count (#126 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
248 of 264 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
265 total, page 3 of 6
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
NCT00409578
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
NCT00414024
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
NCT00701259
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
NCT00431444
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
NCT00441064
Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00581945
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
NCT00428389
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
NCT00376259
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
NCT00390975
Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.
NCT00417196
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
NCT00411099
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
NCT00411242
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
NCT00425997
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
NCT00439244
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
NCT00414609
Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)
NCT00412750
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
NCT00416702
Bioavailability of Aliskiren and Valsartan as a Single Tablet vs. the Same Doses of the Two Drugs Given Separately to Healthy Subjects.
NCT00416728
Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma
NCT00403637
Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.
NCT00417261
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00409708
Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension
NCT00419796
Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis
NCT00426621
Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
NCT00424346
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
NCT00402103
Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects.
NCT00416468
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
NCT00413790
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
NCT00399659
Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers
NCT00416845
Single Dose Study to Assess the Safety, Tolerability, Concentration in Body and Effect of BAF312
NCT00422175
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
NCT00387517
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
NCT00386607
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT00394173
A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
NCT00386139
Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine
NCT00416962
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
NCT00365820
Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients
NCT00348634
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
NCT00350168
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
NCT00389948
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
NCT00390390
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
NCT00353912
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
NCT00355134
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
NCT00366002
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
NCT00340834
8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension
NCT00327587
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
NCT00305903
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
NCT00447694
Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder
NCT00301236
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
NCT00290771
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes
NCT00380445
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 46 |
| Phase 3 | 126 |
| Phase 4 | 50 |
Therapeutic Areas
How the Novartis archive is shaped
265 indexed studies, none listed as recruiting (0% open); 248 completed (94%).
Phase mix: 176 late (III/IV) vs 69 early (I/II) (later-stage heavy).
Top condition: Hypertension (11 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Novartis: archived-pipeline peers nationwide
Peers matched on 265 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Novartis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 265 archived trials
- Abbott Medical Devices · 261 trials · 9% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
- Pennington Biomedical Research Center · 258 trials · 13% recruiting
- University of Texas at Austin · 257 trials · 23% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Novartis page
265 registered trials is a research-attention snapshot, not an endorsement of Novartis or any single study.
- None of Novartis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypertension is the condition Novartis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Novartis pipeline card: 265 registered trials from official public datasets.Report a data error.